Race Oncology Limited

RAC

AU000000RAC3

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:05 2024-04-29 am EDT			5-day change	1st Jan Change
1.3 ^AUD	-0.76%		+1.96%	+54.76%

Mar. 26	Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	MT
Mar. 18	Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	CI

Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index

March 17, 2024

Latest news about Race Oncology Limited

Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	Mar. 25	MT
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	Mar. 17	CI
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment	Mar. 06	MT
Race Oncology Widens Loss in Fiscal H1	Feb. 27	MT
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Race Oncology Names CEO; Shares Jump 5%	Nov. 21	MT
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer	Nov. 21	CI
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	23-10-05	MT
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index	23-09-18	CI
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Race Oncology Limited Announces Board Changes	23-08-21	CI
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	23-07-12	MT
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	23-07-12	CI
Race Oncology Signs Manufacturing Deal for Intravenous Formulation; Shares Fall 4%	23-07-11	MT
Race Oncology Limited Executes Global License Agreement with City of Hope to Access FTO IP	23-07-10	CI
Race Oncology Secures License Deal for Cancer Research Intellectual Property	23-07-10	MT
Race Oncology Limited Announces Board Changes	23-06-28	CI
Tranche Update on Race Oncology Limited's Equity Buyback Plan announced on June 9, 2022.	23-06-22	CI
Race Oncology Limited's Equity Buyback announced on June 9, 2022, has closed with 634,881 shares, representing 0.40% for AUD 1.28 million.	23-06-21	CI
Race Oncology Names Chief Medical Officer	23-05-09	MT
Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023	23-05-08	CI
Race Oncology Releases Detailed Commercial Assessment for Zantrene's Market Potential; Shares Jump 7%	23-04-13	MT
Race Oncology Receives AU$1.5 Million R&D Tax Rebate	23-03-27	MT
Race Oncology Scientific Chief to Step Down; Shares Fall 10%	23-03-23	MT
Race Oncology Limited Announces Management Changes	23-03-23	CI

Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RACE ONCOLOGY LIMITED	+54.76%	142M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B